Our Firm is representing hundreds of women who allegedly suffered many of the vaginal mesh complications noted in the Public Citizen letter. We have been monitoring this matter closely.
New York, New York (PRWEB) July 25, 2014
As thousands of transvaginal mesh lawsuits (http://www.transvaginalmeshlawsuithelp.com/) move forward in U.S. courts, Bernstein Liebhard LLP notes that the Food & Drug Administration (FDA) has rejected a petition by the consumer advocacy group, Public Citizen, to order a global recall of all transvaginal mesh products. In a letter dated May 1, 2014, and released to the public last week, the agency also rejected the group’s petition for a ban on the marketing of all surgical mesh devices used in the transvaginal repair of pelvic organ prolapse. According to the letter, the FDA agreed that the use of such products in prolapse repair is associated with post-operative complications such as mesh exposure and extrusions, vaginal scarring, pelvic pain, and infection. However, the letter maintained that a transvaginal mesh recall or ban is not warranted at this time.*
“Our Firm is representing hundreds of women who allegedly suffered many of the vaginal mesh complications noted in the Public Citizen letter. We have been monitoring this matter closely,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free transvaginal mesh lawsuit reviews to women who suffered mesh erosion, pain, scarring, infection and other serious injuries, allegedly due to products manufactured by American Medical Systems, Inc., Boston Scientific Corp., C.R. Bard, Inc. and Ethicon, Inc.
Vaginal Mesh Complications
The FDA did launch a review of transvaginal mesh products in October 2008, and alerted the public to the serious risks associated with these devices at that time. In July 2011, the agency issued a second alert after it received thousands of additional reports of injuries associated with transvaginal mesh. This past April, the FDA proposed reclassifying vaginal mesh used to treat pelvic organ prolapse as high-risk medical devices, which would subject the devices to greater regulatory scrutiny.
According to court documents, more than 60,000 transvaginal mesh lawsuits have since been filed in courts throughout the U.S. by women who allegedly suffered pain, mesh erosion, organ damage and other serious vaginal mesh complications following surgery to treat pelvic organ prolapse or stress urinary incontinence. Bernstein Liebhard LLP partner, Jeffrey S. Grand, is serving on the Plaintiffs’ Steering Committees for a number of mesh proceedings underway in U.S. District Court, Southern District of West Virginia, including those involving American Medical Systems, Inc. (MDL No. 2325), Boston Scientific Corp. (MDL No. 2326), C.R. Bard, Inc. (MDL No. 2187) and Ethicon, Inc. (MDL No. 2327).
Mr. Grand has also been appointed Co-Liaison Counsel in two multicounty litigations underway in New Jersey Superior Court for transvaginal mesh lawsuits involving products marketed by C.R. Bard and Ethicon. He was also a member of the Plaintiff’s trial team on the first Ethicon trial in that proceeding, which ended in March 2013 with a jury awarding $11 million in compensatory and punitive damages to a woman who was harmed by the Ethicon Gynecare Prolift device. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10; In re: Pelvic Mesh Litigation/Bard, No. L-6339-10)
Alleged victims of serious vaginal mesh complications may be able to pursue their own legal claim against the manufacturer of their device. To learn more about the ongoing transvaginal mesh litigation, please visit Bernstein Liebhard LLP's website or the Firm's Facebook page: https://www.facebook.com/meshlawsuit. To obtain a free, confidential and no-obligation case review, please call 800-511-5092.
*http://www.regulations.gov/#!documentDetail;D=FDA-2011-P-0641-0007, FDA, May 2, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP